Rhabdomyosarcoma - Pipeline Review, H1 2018

  • ID: 4518493
  • Drug Pipelines
  • 263 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Celgene Corp
  • Eisai Co Ltd
  • Iproteos SL
  • Morphotek Inc
  • Noxxon Pharma AG
  • MORE
Rhabdomyosarcoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H1 2018, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 17, 3, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Celgene Corp
  • Eisai Co Ltd
  • Iproteos SL
  • Morphotek Inc
  • Noxxon Pharma AG
  • MORE
Introduction

Rhabdomyosarcoma - Overview

Rhabdomyosarcoma - Therapeutics Development

Rhabdomyosarcoma - Therapeutics Assessment

Rhabdomyosarcoma - Companies Involved in Therapeutics Development

Rhabdomyosarcoma - Drug Profiles

Rhabdomyosarcoma - Dormant Projects

Rhabdomyosarcoma - Discontinued Products

Rhabdomyosarcoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Rhabdomyosarcoma - Pipeline by Amgen Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Rhabdomyosarcoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Rhabdomyosarcoma - Pipeline by Celgene Corp, H1 2018

Rhabdomyosarcoma - Pipeline by Cellectar Biosciences Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Cellestia Biotech AG, H1 2018

Rhabdomyosarcoma - Pipeline by Eisai Co Ltd, H1 2018

Rhabdomyosarcoma - Pipeline by Epizyme Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Exelixis Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Iproteos SL, H1 2018

Rhabdomyosarcoma - Pipeline by Ipsen SA, H1 2018

Rhabdomyosarcoma - Pipeline by MacroGenics Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Morphotek Inc, H1 2018

Rhabdomyosarcoma - Pipeline by NantKwest Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Novartis AG, H1 2018

Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H1 2018

Rhabdomyosarcoma - Pipeline by Pfizer Inc, H1 2018

Rhabdomyosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Rhabdomyosarcoma - Pipeline by Taiwan Liposome Company Ltd, H1 2018

Rhabdomyosarcoma - Pipeline by Tarveda Therapeutics Inc, H1 2018

Rhabdomyosarcoma - Dormant Projects, H1 2018

Rhabdomyosarcoma - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Bellicum Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Cellectar Biosciences Inc
  • Cellestia Biotech AG
  • Eisai Co Ltd
  • Epizyme Inc
  • Exelixis Inc
  • Iproteos SL
  • Ipsen SA
  • MacroGenics Inc
  • Morphotek Inc
  • NantKwest Inc
  • Novartis AG
  • Noxxon Pharma AG
  • Pfizer Inc
  • Taiho Pharmaceutical Co Ltd
  • Taiwan Liposome Company Ltd
  • Tarveda Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll